John Babiak, senior vice president of drug discovery technologies at PTC Therapeutics in South Plainfield, New Jersey, which is developing and testing PTC124, shrugs off the NIH work. (sciencemag.org)
In 2004, he founded and served as CEO of PAI Life Sciences Inc., a bioinformatics company with proprietary drug discovery technologies using artificial neural nets. (idri.org)
He was key in developing fragment - based drug discovery technologies that formed the basis for numerous corporate partnerships, including inventorship of a fragment - based technology that attracted more than $ 150 million in partner revenue and equity investments. (carmot-therapeutics.us)